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In recent years, the use of blood products has come under increased scrutiny in an effort to 
optimize the use of medical resources. We assembled a working group and developed a set of 
evidence based recommendations for red blood cell (RBC) transfusions at the Johns Hopkins 
Bloomberg Children’s Center (JHBCC). Before implementing the guidelines, we began our 
studies by using a national surgical dataset to develop regression models that allow for 
benchmarking of transfusion practices in surgical patients between hospitals (Chapter 1). We 
then characterized the allocation of RBC to specific high-risk surgeries and found that more than 
half of the transfusions in children’s surgery are associated to only two procedures: spinal fusion 
for arthrodesis and craniectomy for craniosynostosis (Chapter 2).  
 
Once our guidelines were finalized, we embedded them into a clinical decision support (CDS) 
logic within our computerized provider ordering system. This intervention reminded providers of 
the evidence-based guidelines when attempting to transfuse outside of recommended thresholds. 
We analyzed the effect of the CDS mechanism by comparing incidence rates of transfusion 
(Chapter 3). We used a zero-inflated negative binomial regression model to adjust for covariates 
while using historical controls. The CDS intervention was associated with a decrease of blood 
transfusions in patients >3 months of age (IRR 0.818, p<0.001) but not in patients <3 months 
(IRR 0.972, p=0.739).  
 
The ascertainment of pre and post-transfusion hemoglobin values during the year of the 
intervention allowed us to investigate adherence to the newly created JHBCC guidelines 
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(Chapter 4). From 1955 transfusions, 41.6% were compliant with institutional recommendations 
(46.7% in patients <3 months and 35.1% in patients >3 months). Lastly, we studied the different 
approaches that hospital units have in relation to volume of RBC ordered. While there are 
differences in comorbidity profiles of patients between hospitals units, we found that similar 
patients are transfused different volumes depending on where they are admitted to. 
 
These analyses and their results are unique as they describe sophisticated methods and 
interventions that can serve pediatric practitioners be better informed and improve the use of 
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Several studies have shown a high variability in transfusion practices in pediatric hospitals. This 
variability is likely explained in part by varying patient populations and procedures being 
performed. Therefore an accurate method of comparing blood utilization between centers 
becomes vital. 
 
Data from the National Surgical Quality Improvement Program-Pediatric from 2012 to 2015 
were used. Patients were stratified in two age groups (0-3 months and 3 months to 18 years) We 
used a forward-stepwise logistic regression approach and developed a model for each age group 
with data from 2012 and 2014. The models were validated with data from 2013 and 2015. The 
model for patients <3 months included 18 variables and had excellent discriminatory 
performance (area under the curve 0.866). The model for patients >3 months to 18 years had 21 
variables and an area under the curve of 0.916. In conclusion, multiple preoperative factors have 
been built into a risk-adjusted model for blood utilization that can be used for benchmarking 









Several studies have shown a high variability in transfusion practices in pediatric hospitals.1–3 
This variability is likely explained in part by varying patient populations and procedures being 
performed. Therefore an accurate method of comparing blood utilization between centers 
becomes vital. The models put forth in this study can provide such a method by allowing 







Data from the American College of Surgeons (ACS) National Surgical Quality Improvement 
Project – Pediatric (NSQIP-P) Participant Use Data Files (PUFs) from 2012 to 2015 were 
utilized for this analysis. As stated in the previous chapter, the PUFs contain information on 30-
day outcomes on pediatric surgical patients from more than 100 hospitals in the United States, 
two in Australia, and one in the United Arab Emirates. Pediatric patients were defined as 0 to 18 
years of age. A transfusion was defined as an occurrence in which the patient received packed 
red blood cells, whole blood, or autologous blood transfusion from the surgery start time until 72 
hours after. Transfusions received before surgery start time or other blood products (e.g. fresh 
frozen plasma, platelets, etc.) were not included. The term perioperative transfusion is used for 
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intraoperative and postoperative transfusions, and the perioperative period is defined as a 72 hour 
window by NSQIP. 
 
Patients were stratified by perioperative transfusion status (transfused vs. not transfused) and 
compared according to demographic and clinical characteristics (sex, age category, 
race/ethnicity, surgical specialty, prematurity, number and day of transfusion occurrence) using 
chi-square tests. Age was grouped into 4 categories: 0-3 months, 3 months-1 year, 1-10 years, 
≥10 years. Race/ethnicity was categorized as White, Black, Asian, Hispanic, American Indian, 
Pacific Islander and Unknown. Specialty is a defined variable by NSQIP-P based on the 
operating surgeon. 
 
Model Development and Validation 
 
To develop an adjustment model for transfusion, a forward-stepwise logistic regression analysis 
was performed using data from the 2012 and 2014 PUFs. The significance level for variable 
addition was set at 0.05. Due to the significant differences among comorbidities and types of 
surgeries, two different models were designed, one for patient 0-3 months of age and another one 
for 3 months to 18 years of age. All preoperative variables available in NSQIP were tested for 
model construction, with the exception of variables that were not available for all the PUFs 
studied (e.g. laparoscopic/open approach was not available for 2012, and dialysis was 
discontinued in 2015) and non-relevant variables for the 0-3 month age group (e.g. cystic 
fibrosis, diabetes). The final models included 30 variables for 0-3 months of age and 34 variables 




The analysis for patients 0-3 months of age included 30 potential preoperative variables: 
ventilator dependence, bronchopulmonary dysplasia/chronic lung disease, oxygen requirement, 
tracheostomy, structural pulmonary/airway abnormalities, cardiac risk factors (factor), previous 
cardiac surgery, developmental delay/impaired cognitive status, seizure disorder, cerebral palsy, 
neuromuscular disorder, IVH grade (factor), steroid use within 30 days, nutritional support, 
systemic inflammatory response syndrome/sepsis/septic shock, inotropic use, prior 
cardiopulmonary resuscitation, congenital malformation (factor- no; yes neonate 1500g at time 
of surgery; yes- neonate 1500g at time of surgery or patient with history of congenital defect at 
time of surgery), preoperative transfusion within 48 hours, sex, inpatient/outpatient status, race 
(factor), ASA (American Society of Anesthesiologists) class (factor), surgical specialty (factor), 
prematurity (factor), hematologic disorder, malignancy (factor- no cancer; history of; current), 
open wound, transfer status (factor), esophageal/gastric/intestinal disease. 
 
For the ≥3 months of age model, 34 initial variables were analyzed for potential inclusion into 
the model: the same variables as the model for 0-3 months plus diabetes (factor- no; insulin 
dependent; non-insulin dependent), asthma, cystic fibrosis, age category (factor- 3 months to 1 
year; 1 year to 10 years; 10 years). Correlation between variables was investigated by 
displaying a correlation matrix. The models built using 2012 and 2014 data were validated using 
the 2013 and 2015 PUF. The area under a receiver operating characteristics (ROC) curve (AUC) 
was calculated for each model to test discrimination performance. The Hosmer-Lemeshow test 
was calculated to assess goodness of fit using the number of covariates of the final model plus 






A total of 369,176 surgeries were utilized for analysis. Perioperative transfusions occurred in 
21,410 (5.8%) of cases (Table 1.1). Female patients were transfused more frequently than males 
(7.3% vs 4.7%, p<0.001). Patients 0 to 3 months of age were transfused more frequently (8.96%) 
than older patients (3mo-1year, 6.7%; 1-10 years 2.5%; ≥10years 8.1%, p<0.001). Black race 
was associated with a higher proportion of transfusions (7.6%, p<0.001). The surgical specialty 
with the highest proportion of transfused cases was Orthopedic Surgery (15.4%, p<0.001). 
General Surgery had a transfusion occurrence in 4.3% of the cases. The combination of spine 
cases (extracted from Orthopedic Surgery and Neurosurgery) had a transfusion rate of 41.2%. 
For patients less than three months of age, prematurity was significantly associated with a 
transfusion requirement (24.8% vs. 6.3%, p<0.001). The majority of cases that were transfused 
required only 1 transfusion (98.3%) in the perioperative period. 82.4% of transfusions occurred 
on the day of surgery. 
 
The forward stepwise regression analyses yielded an 18-variable model for patients 0-3 months 
of age. The variables for the 0-3 month model were (in order of forward selection): ventilator 
dependence, ASA class, prematurity, preoperative transfusion, SIRS/sepsis/septic shock, 
malignancy, nutritional support, surgical specialty, hematologic disorder, inpatient status, 
inotropic support, IVH grade, transfer/origin status, prior CPR, oxygen support, steroid use, sex 
and race. The variables with the largest association with transfusion were malignancy (current 
malignancy OR 15.67 [95%CI 7.90-31.08], history of cancer OR 34.11 [3.29-353.66]), ASA  
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Table 1.1 Population Characteristics by Transfusion Status 
 Transfused, n(%) Not transfused, n(%) p 
Sex       
   Female 11,576 (7.3) 147,824 (92.7)  
   Male 9,834 (4.7) 199,942 (95.3) <0.001 
Age categories    
    0-3 months 3,758(11.4) 29,329 (88.6)  
   3 months to 1 year 2,988 (6.7) 41,446 (93.3)  
   1 to 10 years 3,987 (2.5) 155,609 (97.5)  
   ≥10 years 10,677 (8.1) 121,382 (91.9) <0.001 
Race/Ethnicity    
   White 12,624 (5.8) 207,071 (94.3)  
   Black 3,612 (7.6) 43,755 (92.4)  
   Asian 639 (4.7) 10,637 (95.3)  
   Hispanic 1,834 (4.5) 38,881 (95.5)  
   American Indian 85 (5.5) 1,463 (94.5)  
   Pacific Islander 65 (4.8) 1,291 (95.2)  
   Unknown 2,662 (5.6) 44,668 (94.4) <0.001 
Specialty    
   General 6,105 (4.3) 137,073 (95.7)  
   Orthopedic 10,762 (15.4) 59,013 (84.6)  
   Urology 236 (0.6) 40,689 (99.4)  
   Neuro 2,468 (7.1) 32,329 (92.9)  
   ENT 220 (0.5) 45,934 (99.5)  
   Plastic 1,603 (4.8) 31,892 (95.2)  
   Gynecology 16 (1.9) 836 (98.1)  
   Spine * 9,722 (41.2) 13,856 (58.8) <0.001 
Premature (if <3months)    
   No 1,500 (6.3) 22,472 (93.7)  
   Yes 2,258 (24.8) 6,857 (75.2) <0.001 
n of transfusions    
   1 21,052 (98.3) -  
   2 305 (1.4) -  
   ≥3 53 (0.04) - na 
Postop day of transfusion    
   0 17,633 (82.4) -  
   1 2,092 (9.8) -  
   2 1,207 (5.6) -  




(Table 1.1 cont)  




class (class 4 OR 11.91 [6.50-21.80], class 5 OR 12.00 [5.53-26.03]),  surgical specialty 
(orthopedic OR 3.36 [1.73-6.50], plastic OR 4.42 [2.66-7.34]) and prematurity (25-26 weeks of 
gestational age OR 4.12 [2.94-5.79]). The AUC on the developing model was 0.8723, and the 
AUC was 0.8655 on the validation dataset. The Hosmer-Lemeshow goodness-of-fit test had a 
p<0.001 (Table 1.2). 
 
The final model for patients >3 months of age included 21 variables (in order of forward 
selection): neuromuscular disorder, inpatient status, surgical specialty ASA class, age category, 
transfer/origin status, malignancy, hematologic disorder, inotropic support, sex, 
SIRS/sepsis/septic shock, cerebral palsy, preoperative transfusion, congenital malformation, 
nutritional support, race, cardiac risk factors, oxygen support, tracheostomy, IVH grade and 
steroid use. The variables with the largest association with transfusion were ASA class (class 5 
OR 27.19 [95%CI 12.64-58.49], class 4 OR 6.29 [5.20-7.60]), surgical specialty (orthopedic OR 
17.44 [15.71-19.37], plastic OR 5.22 [4.55-5.99]) and inpatient status (OR 16.49 [14.45-18.82]).    
The AUC on the developing model was 0.9189, and the AUC was 0.9163 on the validation 
dataset. The Hosmer-Lemeshow goodness-of-fit test p value was <0.001 (Table 1.3). None of the 






Table 1.2 Logistic regression model for transfusion outcome. Patients 0-3 months of age. 
Variable OR SE z P [95% CI] 
Ventilator Dependance 1.57 0.16 4.5 <0.001 [1.29-1.91] 
ASA Classification      
   2 2.73 0.82 3.33 0.001 [1.51-4.94] 
   3 6.02 1.81 5.95 <0.001 [3.33-10.86] 
   4 11.91 3.67 8.03 <0.001 [6.50-21.80] 
   5 12.00 4.74 6.29 <0.001 [5.53-26.03] 
Prematurity (wga)      
   35 to 36 1.14 0.14 1.12 0.263 [0.91- 1.44] 
   33 to 34 1.58 0.22 3.35 0.001 [1.21-2.07] 
   31 to 32 2.21 0.36 4.85 <0.001 [1.61-3.05] 
   29 to 30 2.42 0.43 4.97 <0.001 [1.71-3.42] 
   27 to 28 2.82 0.47 6.19 <0.001 [2.03-3.92] 
   25 to 26 4.12 0.71 8.21 <0.001 [2.94-5.79] 
   24 2.05 0.51 2.88 0.004 [1.26-3.34] 
   <24 3.38 1.06 3.88 <0.001 [1.83-6.26] 
Preoperative Transfusion 1.97 0.23 5.92 <0.001 [1.58-2.47] 
Preoperative Sepsis/SIRS/Shock      
   SIRS 1.71 0.45 2.01 0.045 [1.01-2.87] 
   Sepsis 3.41 0.64 6.58 <0.001 [2.37-4.91] 
   Septic Shock 2.44 0.69 3.12 0.002 [1.39-4.26] 
Malignancy      
   Current 15.67 5.48 7.87 <0.001 [7.90-31.08] 
   History of cancer 34.11 40.70 2.96 0.003 [3.29-353.66] 
Nutritional Support 1.68 0.14 6.24 <0.001 [1.43-1.98] 
Surgical Specialty (ref. General)      
   Orthopedic 3.36 1.13 3.59 <0.001 [1.73-6.50] 
   Urology 1.35 0.37 1.08 0.28 [0.78-2.31] 
   Neuro 1.02 0.13 0.15 0.878 [0.79-1.32] 
   ENT 0.22 0.08 -4.31 <0.001 [0.11-0.44] 
   Plastic 4.42 1.14 5.73 <0.001 [2.66-7.34] 
Hematologic Disorder 1.74 0.17 5.53 <0.001 [1.43-2.11] 
Inpatient status (ref. outpatient) 3.92 1.13 4.75 <0.001 [2.23-6.89] 
Inotropic Support  1.48 0.22 2.6 0.009 [1.10-1.98] 
IVH grade      
   1 1.49 0.33 1.84 0.065 [0.97-2.29] 
   2 0.53 0.15 -2.27 0.023 [0.30-0.92] 
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   3 0.63 0.17 -1.74 0.082 [0.38-1.06] 
   4 0.58 0.13 -2.43 0.015 [037-0.90] 
   Unknown 0.37 0.15 -2.39 0.017 [0.17-0.84] 
Transfer/Origin status (ref. admitted 
from home)      
   Admitted through ER 0.61 0.08 -3.65 <0.001 [0.47-0.79] 
   Outside Hospital 0.83 0.08 -2.01 0.045 [0.69-1.00] 
   Other 0.76 0.10 -2.03 0.042 [058-0.99] 
Prior CPR 1.83 0.44 2.5 0.012 [1.14-2.94] 
Oxygen support 1.25 0.12 2.39 0.017 [1.04-1.49] 
Steroid use 1.41 0.20 2.45 0.014 [1.07-1.86] 
Female (ref. male) 1.19 0.09 2.41 0.016 [1.03-1.38] 
Race/Ethnicity (ref. white)      
   Black 1.37 0.14 3.16 0.002 [1.13-1.66] 
   Asian 0.83 0.21 -0.75 0.454 [0.50-1.36] 
   Hispanic 1.03 0.14 0.2 0.845 [0.78-1.34] 
   American Indian 1.00 0.49 0.01 0.994 [0.39-2.60] 
   Pacific Islander 2.20 1.39 1.24 0.214 [0.63-7.62] 
   Unknown 0.96 0.10 -0.41 0.685 [0.78-1.18] 
# observations: 10,864      
# transfusions: 1,263 (11.6%)      
AUC: 0.8723      
HL-value: 25.23 (p<0.001)           
ASA, American Society of Anesthesiologists; wga, weeks of gestational age; SIRS, systemic inflammatory 





This study used a large national dataset to develop risk-adjusted models for transfusion use. We 
identified multiple patient characteristics, outside of the type of procedure, that were strongly 
associated with transfusion use and should be accounted for when benchmarking transfusion 




Table 1.3 Logistic Regression Model for Transfusion Outcome. Patients ≥3 Months of Age 
Variable OR SE z P [95% CI] 
Neuromuscular Disorder 1.38 0.07 6.45 <0.001 [1.25-1.52] 
Inpatient status (ref. outpatient) 16.49 1.11 41.59 <0.001 [14.45-18.82] 
Surgical Specialty (ref. General)      
   Orthopedic 17.44 0.93 53.56 <0.001 [15.71-19.37] 
   Urology 0.53 0.07 -4.64 <0.001 [0.41-0.70] 
   Neuro 2.20 0.13 13.06 <0.001 [1.95-2.47] 
   ENT 0.22 0.04 -7.66 <0.001 [0.15-0.32] 
   Plastic 5.22 0.37 23.63 <0.001 [4.55-5.99] 
   Gyn 1.23 0.53 0.47 0.637 [0.53-2.86] 
ASA Classification      
   2 1.72 0.08 11.27 <0.001 [1.56-1.89] 
   3 2.66 0.15 17.32 <0.001 [2.38-2.97] 
   4 6.29 0.61 19.00 <0.001 [5.20-7.60] 
   5 27.19 10.63 8.45 <0.001 [12.64-58.49] 
Age Categories (ref. 3mo -1 year)      
   1-10 years 0.25 0.01 -25.54 <0.001 [0.22-0.27] 
   ≥10 years 0.62 0.03 -9.02 <0.001 [0.55-0.68] 
Transfer/Origin status (ref. admitted from 
home)      
   Admitted through ER 0.27 0.02 -22.54 <0.001 [0.24-0.30] 
   Rehabilitation Facility 0.73 0.26 -0.88 0.378 [0.37-1.46] 
   Outside Hospital 0.87 0.08 -1.49 0.136 [0.73-1.04] 
   Other 2.00 0.24 5.75 <0.001 [1.58-2.53] 
Malignancy      
   Current Cancer 4.34 0.30 21.07 <0.001 [3.79-4.98] 
   Past History of Cancer 0.73 0.13 -1.78 0.075 [0.52-1.03] 
Hematologic Disorder 2.64 0.18 14.05 <0.001 [2.31-3.02] 
Inotropic Support 4.62 0.63 11.26 <0.001 [3.54-6.04] 
Female (ref. male) 1.37 0.04 9.81 <0.001 [1.28-1.45] 
Preoperative Sepsis/SIRS/Shock      
   SIRS 1.49 0.20 2.99 0.003 [1.15-1.94] 
   Sepsis 2.19 0.28 6.13 <0.001 [1.70-2.82] 
   Septic Shock 4.63 1.31 5.41 <0.001 [2.66-8.06] 
Cerebral Palsy 0.66 0.04 -6.67 <0.001 [0.58-0.75] 
Preoperative Transfusion 1.88 0.22 5.38 <0.001 [1.50-2.37] 
Congenital Malformation 1.23 0.04 5.82 <0.001 [1.15-1.32] 
Nutritional Support 1.36 0.08 5.27 <0.001 [1.21-1.52] 
Race      
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   Black 0.97 0.04 -0.57 0.570 [0.89-1.07] 
   Asian 0.62 0.07 -4.36 <0.001 [0.50-0.77] 
   Hispanic 0.88 0.05 -2.20 0.028 [0.78-0.99] 
   American Indian 1.19 0.27 0.75 0.451 [0.76-1.87] 
   Pacific Islander 0.89 0.30 -0.34 0.735 [0.46-1.73] 
   Unknown 0.81 0.04 -4.00 <0.001 [0.73-0.90] 
Cardiac Risk Factors      
   Minor 0.77 0.05 -3.90 <0.001 [0.67-0.88] 
   Major 0.84 0.07 -2.10 0.036 [0.71-0.99] 
   Severe 0.66 0.11 -2.63 0.008 [0.48-0.90] 
Oxygen Support 1.44 0.12 4.28 <0.001 [1.22-1.70] 
Presence of tracheostomy 0.64 0.07 -3.84 <0.001 [0.51-0.80] 
IVH grade      
   1 1.65 0.36 2.28 0.023 [1.07-2.53] 
   2 1.07 0.29 0.24 0.810 [0.62-1.83] 
   3 0.64 0.17 -1.65 0.098 [0.37-1.09] 
   4 0.52 0.11 -3.07 0.002 [0.34-0.79] 
   5 0.80 0.15 -1.20 0.229 [0.55-1.15] 
Steroid use 1.23 0.10 2.60 0.009 [1.05-1.43] 
# records: 108,676      
# transfusions:  5,842 (5.4%)      
AUC: 0.9189      
HL-chi2: 60.94 (p<0.001)           
ASA, American Societa of Anesthesiologists; SIRS, systemic inflammatory response syndrome; ER, emergency 
room; IVH, intraventricular hemorrhage; ENT, ears, nose and throat. 
 
Stey et.al. published a model for non-neonate pediatric surgical patients using NSQIP-P data.1 
Their methodology is similar to the one utilized by the ACS when reporting outcomes to 
participating institutions. Unfortunately, these hierarchical methods cannot be universally 
utilized by the participating hospitals because variables such as hospital IDs and CPT outcome-
specific risk are not included in the PUF.  Notably, the logistic regression models in the present 
study were instead built only with variables that are available to other centers. Utilizing only 
these variables, the models still maintained excellent statistical performance. The AUC for the 
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model in the validation set for the 0-3 months group was 0.867 and in the >3 months group was 
0.916. The goodness-of-fit test showed poor calibration of the data, but this finding is very 
common when using large datasets where minimal differences in observed to expected 
occurrences have a big impact in the statistical significance of the test.4 
 
Premature neonates are at high risk of requiring blood transfusions, and their physiology and 
dynamic definition of anemia has made them difficult to study. In the study by Stey and 
associates, patients younger than 28 days were excluded from the study because of their differing 
physiology and surgical profile compared to other pediatric patients. The present work 
contributes a model specifically for patients younger than 3 months of age. The magnitude of the 
variables association with transfusion is significantly different and variables like ventilator 
dependence, prematurity and prior CPR became increasingly relevant when examining patients 
<3 months of age compared to older children. 
 
NSQIP-P provides risk-adjusted outcome reports to participating centers in a semi-annual basis. 
The individual outcome of a perioperative transfusion is not reported; instead it is bundled with 
other morbidity (e.g. pneumonia, reintubation, pulmonary embolism, etc.) and defined as a 
composite outcome. In 2018, transfusions began to be reported as an individual occurrence but 
just for the CPT codes related to spinal fusion. Therefore, the only way of studying risk-adjusted 
models of transfusion is by analyzing the PUF. 
 
Centers with access to the PUF can follow similar regression techniques and create models for 
benchmarking specific outcomes of interest and CPT codes. Maizlin and colleagues utilized 
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NSQIP-P data to develop a predictive model for pediatric wound infections.5 Bartz-Kuricky and 
associates created a model to study the effect of cardiac risk factors on outcomes of children 
undergoing cranial vault remodeling.6 Similar to this study, they were unable to perform a 
hierarchical regression as the PUF does not contain a specific variable to define hospitals. 
Nevertheless, the results of a hierarchical versus traditional logistic regression model have been 
compared using NSQIP data, and both types of models yield nearly identical results.7  
 
This study has several limitations. The regression analyses in this study are dependent on 
preoperative variables and do not account for the operative procedure. While this allows for a 
simpler model, it likely has an effect on the statistical performance of the models. Third, due to 
the fact that hospital IDs are not available in the PUF, this study could not evaluate the effect of 
the model in multiple individual hospitals. If interested in studying their risk-adjusted transfusion 
practices compared to NSQIP-P universe, participating centers can request to the ACS an 
identification of PUF entries that belong to their institution and perform this analysis. We tested 
the model in one of the authors’ institution PUF entries and the adjustment changed the odds 
ratio from one side of the null to the other, accentuating the importance of using multivariate 
models. Finally, the fact that spinal fusion and craniosynostosis surgery accounted for more than 
half of the transfusions likely leads to increased weighting of variables important to that 
population of patients (e.g. neuromuscular disorders), which may not be as importantly 






Comparison of perioperative transfusion rates among hospitals should account for patient 
demographics and risk factors for the event. In the field of pediatrics, young infants and older 
children have a different surgical profile and a diverse set of risk factors for transfusion. We 
identified multiple factors to adjust for transfusion rates that are independent of the type of 




























In order to target interventions to optimize the use of perioperative blood products it is relevant 
to identify surgeries and risk factors associated with transfusions. Data from the National 
Surgical Quality Improvement Program-Pediatric from 2012 to 2015 were used. CPT (Current 
Procedural Terminology®) codes were grouped to identify the procedures where the most 
transfusions are allocated. A total of 369,176 surgical entries were utilized for analysis. 
Perioperative transfusions occurred in 21,410 (5.8%) of cases. 659 CPT codes were grouped in 
207 clusters. Arthrodesis for spinal deformity comprised 44.5% of transfusion occurrences in the 
dataset and craniectomy for craniosynostosis comprised 8.7%. The majority of RBC transfusions 
used in children’s surgery are concentrated within a relatively few CPT codes. This study assists 














In recent years the use of blood products has come under increased scrutiny in an effort to 
optimize the use of medical resources. Red blood cell (RBC) transfusions have been associated 
with adverse outcomes including surgical site infection and necrotizing enterocolitis.8–10 Several 
randomized trials have shown that restrictive hemoglobin transfusion thresholds are non-inferior 
to more liberal strategies for both neonates and older pediatric patients,11–13 and thus a more 
restrictive approach to transfusion has been recommended. In addition, blood is a non-renewable 
resource that depends solely on the altruism of donors and thus should not be wasted. For these 
and other reasons, RBC transfusions have been identified as an important quality metric, and 
hospitals have put forth significant efforts to decrease their use of blood products.14,15 
 
In order to target interventions to optimize the use of blood products related to surgery, the 
procedures most strongly associated with RBC use must first be identified.  Only then can health 
institutions most efficiently improve their blood transfusions through targeting efforts towards 
surgeries or patients that are at higher risk of bleeding or anemia. The objective of this study was 









Data from the American College of Surgeons (ACS) National Surgical Quality Improvement 
Project – Pediatric (NSQIP-P) Participant Use Data Files (PUFs) from 2012 to 2015 were 
utilized for this analysis. The PUFs contain information on 30-day outcomes on pediatric 
surgical patients from more than 100 hospitals in the United States, two in Australia, and one in 
the United Arab Emirates. Pediatric patients were defined as 0 to 18 years of age. A transfusion 
was defined as an occurrence in which the patient received packed red blood cells, whole blood, 
or autologous blood transfusion from the surgery start time until 72 hours after. Transfusions 
received before surgery start time or other blood products (e.g. fresh frozen plasma, platelets, 
etc.) were not included. The term perioperative transfusion is used for intraoperative and 
postoperative transfusions, and the perioperative period is defined as a 72 hour window by 
NSQIP.  
 
Characterization of Transfusion Use 
 
There were a total of 659 CPT (Current Procedural Terminology®) codes in the database. These 
codes were clustered into 207 groups by similarity of procedures (e.g. one group for codes 22800 
to 22812 for arthrodesis of different spinal segments). Transfusion proportions were investigated 
for individual CPT codes and CPT groups. Cumulative distribution curves were used to visualize 
the volume of transfusions attributed across the number of CPT codes. Statistical analysis was 






There were 659 CPT codes listed in the four years of data. There was a transfusion recorded for 
only 439 of those codes. For CPT codes that occurred at least 10 times, the one with the highest 
proportion of patients transfused was 21175 (i.e. Reconstruction, bifrontal, superior-lateral 
orbital rims and lower forehead, advancement or alteration, with or without grafts), with 752 out 
of 988 (76.1%) cases transfused, although this code only accounted for 3.5% of the total of 
patients transfused. The codes with the highest contributions to the transfusion counts were 
22802 (Arthrodesis, posterior, for spinal deformity, with or without cast; 7 to 12 vertebral 
segments) and 22804 (Arthrodesis, posterior, for spinal deformity, with or without cast; 13 or 
more vertebral segments), accounting for 22.8% and 17.6% respectively, of all the transfusions 
in the dataset. (Table 2.1 & Fig 2.1.A) 
 
Once CPT codes were merged into a shorter list of 207, two groups accounted for more than half 
of the transfusion in the dataset. The procedures related to arthrodesis for spinal deformity (CPT 
codes 22280, 22802, 22804 and 22808) comprised 44.5% of the transfusion occurrences in the 
dataset, and those related to craniectomy for craniosynostosis (CPT codes 61550, 61556, 61557, 




This study used a large national dataset to characterize transfusion use in children’s. The 





Table 2.1. Procedures with Highest Transfusion Proportions 
CPT code(s) CPT code description Total 
Transfused 
(%) 
% of Total 
Transfused 
(n=21,410) 
          
By individual CPT     
21175 
Reconstruction, bifrontal, 
superior-lateral orbital rims 
and lower forehead, 
advancement or alteration, 
with or without grafts 988 752 (76.1) 3.5 
22812 
Arthrodesis, anterior, for 
spinal deformity, with or 
without cast; 8 or more 
vertebral segments 25 19 (76) 0.1 
22804 
Arthrodesis, posterior, for 
spinal deformity, with or 
without cast; 13 or more 
vertebral segments 4,972 3,769 (75.8) 17.6 
47122 
Hepatectomy, resection of 
liver; trisegmentectomy 48 35 (72.9) 0.2 
21180 
Reconstruction, entire or 
majority of forehead and/or 
supraorbital rims; with 
autograft 137 99 (72.3) 0.5 
     
By CPT group     
22280, 22802, 22804, 
22808, 22810, 22812 
Arthrodesis for spinal 
deformity 14,678 9,532 (64.9) 44.5 
61550, 61556, 61557, 
61558, 61559 
Craniectomy for 
craniosynostosis 2,986 1,853 (62.1) 8.7 
47125, 47130 Hepatectomy, total lobectomy 147 83 (56.5) 3.9 
21175, 21779, 21180, 
21230 Reconstruction forehead 1,566 883 (56.4) 4.1 








Fig 2.1.A Cummulative proportion of transfusion by individual CPT (Current Procedural Terminology) codes. Each 
step is one CPT code. The red line is the 0.50 mark. Four CPT codes account for 49.3% of transfusions: 22802 
(Arthrodesis, posterior, for spinal deformity, with or without cast; 7 to 12 vertebral segments), 22804 (Arthrodesis, 
posterior, for spinal deformity, with or without cast; 13 or more vertebral segments, 61559 (Extensive craniectomy 
for multiple cranial suture craniosynostosis) and 21175 (Reconstruction, bifrontal, superior-lateral orbital rims and 
lower forehead, advancement or alteration, with or without grafts). 
 
 
four CPT codes account for half of the intraoperative and postoperative transfusions in children’s 
surgery, and approximately 80% of the transfusions occur within just 10% of the codes. Two 
categories of procedures—arthrodesis for spinal deformity and craniectomy for 
craniosynostosis—accounted for over half of the transfusions. This finding suggests that 
targeting interventions to optimize the use of blood products for these specific surgeries would 




To our knowledge, this is the first study outlining the magnitude of transfusion proportions 
across specific CPT codes in children’s surgery. The high rate of blood utilization in pediatric 
spinal fusions has been studied in surgery-specific analyses. Yoshihara et.al. published trends on 
transfusion rates for scoliosis surgery extracted from the National Inpatient Sample (NIS) 
showing transfusion rates of approximately 20-40% depending on the year (2000-2009).16 That 
reporting is quite different than the 64.9% identified in this study, presumably because of the  
 
 
Fig 2.1.B Cummulative proportion of transfusion by CPT (Current Procedure Terminology) groups. Each step is one 
CPT group. The red line is the 0.50 mark. Two CPT groups account for 53.2% of transfusions: Arthrodesis, 






coding limitations in capturing all transfusions using NIS. Bowen and colleagues conducted a 
single-institution analysis that reported a perioperative allogeneic transfusion rate of 57% in this 
same kind of surgeries.17 NSQIP-P includes cell salvage methods such as Cell Saver in the 
definition of transfusion, which may offer an explanation for the small difference between our 
reported rate and the one from Bowen et.al. Part of the impetus for decreasing blood transfusion 
is to decrease exposure to allogeneic products. It is important to consider that an unaccounted 
for, and center-dependent, proportion of transfusions reported in NSQIP-P are from autologous 
blood. 
 
Similar to scoliosis surgery, transfusion use in craniosynostosis surgery has also been a topic of 
interest. This study identified that 62.1% of patients undergoing craniosynostosis surgery  
receive a transfusion, comparable to the rates reported in a systematic review by Lu et.al..18 
Interventions such as the use of preoperative iron supplementation, erythropoietin, autologous 
pre-donation, intraoperative tranexamic acid, and cell salvage have been suggested for both 
scoliosis and craniosynostosis operations.19–21 It is important to mention that a significant 
limitation of this study is that our data source, NSQIP-P, excludes cardiac and transplant surgery 




The majority of RBC transfusions used in children’s surgery are concentrated within a relatively 
few CPT codes. As the appropriate use of blood products becomes more scrutinized, this study 
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assists health centers in focusing optimization efforts on common surgeries with high transfusion 




























A blood transfusion can be a life-saving intervention for a bleeding or anemic patient. However, 
as most treatments provided in medical care, an overuse of blood transfusion can also lead to an 
increase in both costs and complications. Using the results from high-quality randomized trials, 
evidence-based guidelines for transfusion were created as a joint effort from relevant 
stakeholders at the Johns Hopkins Bloomberg Children’s Center (Chapter 4). These guidelines 
were embedded in a clinical decision support (CDS) logic into our computerized provider 
ordering system. The effect of this intervention in transfusion rates was analyzed using historical 
controls in the year immediately prior to the release of the CDS prompt. Several regression 
models were tested and a zero-inflated negative binomial approach was chosen as the best 
predictor of the event. The intervention was associated with a significant decrease in transfusion 
rates in patients >3 months of age (IRR 0.818, p<0.001) but not for patients <3 months (IRR 
0.972, p=0.739). The strength of the evidence supporting our guidelines and the use of 
hemoglobin thresholds for transfusion is much higher for older children than for neonates. We 
believe that this was the primary reason for the lack of effect of the CDS intervention. When 
combining both age groups, the reduction in transfusions per patient-day associated to the use of 







A blood transfusion can be a life-saving intervention for a bleeding or anemic patient. However, 
as most treatments provided in medical care, an overuse of blood transfusion can also lead to an 
increase in both costs and complications. The degree of anemia that a stable child can safely 
tolerate before receiving benefit from a blood transfusion has recently been investigated for the 
past 15 years. A randomized trial in critically ill pediatric patients showed that a hemoglobin 
threshold of 7g/dL was associated with non-inferior outcomes when compared to a more liberal 
strategy.12 In extremely low birth weight neonates with anemia of prematurity, restrictive 
thresholds between 7.5 to 11.5  g/dL depending on age and respiratory support were also deemed 
non-inferior to higher thresholds when comparing short-term outcomes, although follow up 
studies have raised concerns for increases in cognitive and neurosensory impairment.11,22 Further 
description of the data behind the JHBCC recommendations for transfusion is described in 
Chapter 4. 
 
Despite this evidence favoring a more conservative approach to blood transfusion in children, 
transition from clinical trial to clinical application can be slow. Several methods have been 
shown to improve adherence to evidence based medicine in hospital care.23 Clinical decision 
support (CDS) tools have been reported as a way to improve a variety of facets of care, including 
antibiotic stewardship, timely removal of urinary catheters, appropriate deep venous thrombosis 
prophylaxis, and prevention of drug interactions.24–27 The use of CDS for blood utilization in 
adults has been very promising. Our institution found a decrease in adult RBC utilization of 
14.3% when combining CDS with an educational campaign.28 Evidence for CDS in pediatric 
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blood utilization, however, is scarce, with only one previous report in a pediatric population and 
one in neonatal intensive care unit (NICU) patients.29,30  
 
The objectives of this study were 1) to implement an evidence-based CDS tool within a 
computerized provider ordering (CPOE) system and 2) to assess its impact on transfusion 







Patient admissions from a single institution were extracted using IMPACT Online (Haemonetics 
Corp., Braintree, MA), which is a web-based blood management portal. IMPACT Online 
contains variables on total use of blood products, length of stay (LOS), hemoglobin level (first, 
nadir and last), diagnosis and procedure codes, age at admission, and a variety of other factors. 
The software collects data on transfusion of all blood products, but this analysis focused on 
allogeneic red blood cell (RBC) transfusions only. A transfusion was defined as a discrete count 
variable for the delivery of RBC (not specific to a particular ml/kg volume). Monthly reports 
were created from September 2012 to August 2014. Patients with age at admission from 0 to 18 
years were included. 
Admissions during which a hemoglobin level was never checked were considered to have no risk 
of transfusion and were therefore excluded from the analysis. Additional exclusions included 
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patients who were on extracorporeal life support, had cardiovascular assist devices placed, or 
underwent transplantation (solid organ or bone marrow) during the hospitalization. Finally 
admissions with a Diagnosis Related Group code of an injury or trauma (codes 901 to 923 and 
955 to 965) and a length of stay (LOS) ≤1 day were excluded as those transfusions were likely 
related to massive transfusion protocols and therefore unlikely to be impacted by any CDS 
intervention. Only admissions that began and ended within the study period were analyzed. If a 
patient was admitted before the intervention but discharged after that entry was removed from 
the dataset to avoid partial exposure to the CDS intervention. 
A subset of surgical patients was created using a definition described previously.31 In brief, 
surgical admissions were defined as those admissions that included a surgical ICD9 code as the 
primary procedure for the admission. ICD9 codes 35.00 to 35.99 were also included to account 
for cardiac surgery patients. Even though this definition does not include all patients that 
underwent an operation during their admission, it encompasses a representative sample of 




The intervention of interest was a CDS tool embedded within the CPOE system. At the time that 
blood transfusion was ordered, the last hemoglobin value on the patient record was automatically 
extracted. A message appeared if the transfusion was not compliant with the hemoglobin 
thresholds defined in institutional recommendations for blood use. These recommendations were 
developed by an institutional working group based upon the best evidence available at that time 
(Table3.1) The message was a “soft” stop that displayed a text reminding the provider of the 
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evidence suggesting that the transfusion may not be necessary and then required the user to 
choose an indication from a list of options before continuing with the order. This message was 
not a “hard” stop preventing the order entirely, but rather the prompt required an extra step to 
justify the transfusion in order to proceed with the order if it was still desired. 
 
The study population was stratified by age at admission: patients zero to 3 months (90 days) of 
age and those >3 months to 18 years. The CPOE prompt was activated by different thresholds 
depending on the age group. For patients 0 to 3 months or in the NICU, the pre-transfusion 
trigger was ≥8.5 g/dL and for older patients it was ≥7g/dL. The institutional recommendations 
allowed for three different hemoglobin thresholds for patients 0 to 3 months of age depending on 
age and need for respiratory support. Since the software algorithm did not allow for this level of 
detail, the CDS prompt for patients <3 months of age included the table of recommendations and 
an option to click on “transfusion is compliant with guidelines” in the list of indications. (Table 
3.1) 
 
The CDS tool was the main intervention of a group of efforts to optimize the use of blood 
products at our institution. Other associated components were dissemination of recommendations 
via wallet-size cards, presentations at grand rounds and educational conferences, and discussions 
at divisional meetings. In order to minimize the magnitude of the effect of the CDS tool, all of 





Table 3.1 Institutional recommendations for hemoglobin 
thresholds for transfusion and exceptional indications 
Patients 0 to 3 months of age or in the NICU 




1 to 7 ≤13.5 g/dL 12.0 g/dL 
8 to 14 ≤12.0 g/dL ≤10.0 g/dL 
≥ 15 ≤10.0 g/dL ≤8.5 g/dL 
   
Indications to transfuse over hemoglobin recommendation: 
Active bleeding   
Hemolysis   
Active cardiac disease  
Active pulmonary disease  
Symptoms attributed to anemia  
Other   
   
Patients > 3 months of age 
< 7 g/dL for all 
   
Indications to transfuse over hemoglobin recommendation: 
Active bleeding   
Active cardiac disease  
Active pulmonary disease  
Acute coronoary or cerebral ischemia  
Primary oncologic disease  
Sickle cell disease   
Other primary hematologic disease  
Other   
NICU, neonatal intensive care unit. 
* respiratory support is defined as any use of oxygen supplementation 
 
The data for a two year period were analyzed: the immediate calendar year prior to the CDS 
intervention was used as a control cohort and compared to the year after the intervention was 
implemented (day 0 being the first day that the CDS tool appeared in the CPOE). 
 




The primary outcome of interest was the difference in the number of transfusions per patient-
day. This was obtained by calculating incidence rates of allogeneic RBC transfusion events 
during the hospital stay of every patient. Secondary outcomes included mean nadir and last 
hemoglobin values for the hospital stay, number of transfusions per patient, LOS, number of 
patients transfused, number of frequently transfused patients (defined as ≥10 transfusions) and 
the number of transfusions given to frequently transfused patients. Demographic variables (age 
and sex), case mix index (CMI, a continuous variable based on the Medicare Severity-Diagnosis 
Related Group weights), and the mean first hemoglobin were analyzed to verify that the 
populations before and after the CDS intervention had similar profiles. The chi-square test was 
used to compare categorical variables, the t test was used to compare means of variables with a 
normal distribution, and a K-sample equality-of-medians test was used for non-parametric 
comparisons. 
 
Transfusion use before and after the CDS intervention was compared using several methods: 1) 
crude incidence rate ratios (IRR), 2) negative binomial (NB) regression models, and 3) zero-
inflated negative binomial (ZINB) regression models. Model performance was compared using 
the Akaike information criterion (AIC).32 The model with the lowest AIC was considered the 
best performing. Multivariate models were adjusted for age in years (only for the age group >3 
months), sex, type of patient (primarily surgical versus not), and CMI. Zero inflated (ZI) 
regression models were utilized due to the high number of patients that were not transfused 
during their hospital stay, and these were inflated with age in years and nadir hemoglobin.. 
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Poisson regression was not utilized since the median and variance of the sample were 
significantly different.  
 
A subset analysis was done to investigate outcomes specifically within surgical patients, and a 
sensitivity analysis was performed excluding patients that were frequently transfused during their 




A total of 23,756 admissions were screened. After applying exclusion criteria, 14,075 pediatric 
admissions were included in the two year analysis, 3,296 in the 0-3 month age group and 10,779 
in the 3 months to 18 years group. (Figure 3.1) 
 
Admissions 0 to 3 months of age 
 
No significant differences were identified in the characteristics of patients before (n=1,612) and 
after (n=1,684) the intervention. Median age at admission was 0 [0-2] before the intervention and 
o [0-0] after, 42.9% of patients were female before the prompt and 44.3% after (p=0.723). The 
mean CMI (MSDRG weights) was 2.12 ±1.44 and 2.09 ±1.45 (p=0.637). The mean first 
hemoglobin was 16.0 ±3.3 and 16.1 ±3.2 for the two time periods (p=0.221). (Table 3.2) 
The incidence of transfusions per patient-day was 0.060 before the intervention and 0.053 after 
(IRR 0.883, p=0.007). (Figure 3.2) The mean nadir (14.6±3.6 vs. 14.8±3.5, p=0.155) and last 
(15.3±3.2 vs. 15.4±3.2, p=0.374) hemoglobin levels were not different in the control and 
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intervention cohorts. A total of 223 (13.8%) patients were transfused in the year before the 
intervention and 219 (13.1%) in the year after (p=0.485). Thirty children were frequently 
transfused (≥10 times) and received 49.9% of the transfusions in the control group, and 18 
patients were frequently transfused and received 35.3% of the transfusions in the intervention 
group (p<0.001). The median LOS was not different between the cohorts (3 days [2-9] vs. 4 days 
[2-9], p=0.413). (Table 3.3) 
 
Fig 3.1 Patient flow chart and exclusion criteria. ECMO, extracorporeal membrane oxygenation; VAD, ventricular 





The incidence of transfusions in surgical patients (n=355) was 0.070 before the intervention and 
0.066  after (IRR 0.951, p=0.542). Secondary outcomes were again similar in the time period 
before and after the intervention. The mean nadir (11.5±2.9 vs. 11.5±3.0, p=0.986) and last 
(13.0±2.7 vs. 12.8±2.9, p=0.653) hemoglobin levels were similar, as well as the number of 
patients transfused (45.1% vs. 41.3%, p=0.469) and LOS (15 days [5-38] vs. 14 days [5-27], 
p=0.548). (Table 3.4) 
 
When excluding the frequently transfused patients, the difference in transfusion incidence before 
and after the intervention was no longer seen. The incidence of transfusions was 0.037 before the 
intervention and 0.039 after (IRR 1.061, p=0.339). The secondary outcomes were also similar: 
nadir mean hemoglobin was 14.7±3.5 vs. 14.9±3.5 (p=0.268) and last hemoglobin was 15.4±3.2 
vs. 15.4±3.2 (p=0.529). (Table 3.5) 
 
Table 3.2 Population Characteristics by Age Group & CDS intervention  









Age,median [IQR] 0 days [0-2] 0 days [0-0] n/a  8 years [3-14] 9 years [3-14] 0.030 
Age category,n (%)        
   0 to 3 months - -   - -  
   3 months to 1y  - -   591 (10.8) 491 (9.3)  
   1 to 10 years - -   2,402 (43.9) 2,319 (43.7)  
   11 to 18 years - -   2,480 (45.3) 2,496 (47.0) 0.017 
Sex, female n(%) 724 (42.9) 746 (44.3) 0.723  2,617 (47.8) 2,579 (48.6) 0.413 
CMI, mean ±SD 2.12 ±1.44 2.09 ±1.45 0.637  1.63 ±1.52 1.66 ±1.54 0.394 
First Hb, mean g/dL 
±SD 
16.0 ± 3.3 16.1 ±3.2 0.221  11.9 ±2.1 11.7 ±2.1 <0.001 





Admissions  >3 months to 18 years 
 
Characteristics of patients before (n=5,473) and after (n=5,306) the intervention were generally 
similar. The median age at admission was slightly younger during the control period (8 years [3-
14] vs 9 years [3-14], p=0.030), likely related to a higher proportion of patients in the 11-18 year 
age group in the intervention group (45.3% vs. 47.0%). In addition, the mean first hemoglobin 
value was slightly higher in the time period before the intervention (11.9±2.1 vs 11.7±2.1, 
p<0.001). (Table 3.2) 
 
Fig 3.2 Monthly rates of transfusions per patient/day for patients <3 months of age or in the neonatal intensive care 
unit. Solid red line is the incidence rate for the 12-month period. Dashed red line is the time of the clinical decision 
support intervention launch. The crude incidence rate ratio (IRR) was 0.883 (p=0.007). The IRR on the multivariate 




The incidence of transfusions per patient-day was 0.067 before the intervention and 0.061 after 
(IRR 0.906, p=0.003). (Figure 3.3) The mean nadir hemoglobin (10.8±2.4 vs. 10.6±2.5, p=0.001) 
and last hemoglobin (11.5±2.0 vs. 11.3±2.0, p<0.001) were slightly lower in the time period after 
the intervention. A total of 726 (13.3%) patients were transfused in the year before the 
intervention and 661 (12.5%) in the year after (p=0.211). Twenty children were frequently 
transfused (≥10 times) and received 13.8% of the transfusions in the control group, and 21 
patients were frequently transfused and received 18.0% of the transfusions in the intervention 
group (p=0.001). The median LOS was not different between the two cohorts (3 days [2-6] vs. 3 
days [2-6], p=0.378). (Table 3.3) 
 
Table 3.3 Secondary Outcomes by Age Group & CDS intervention 









Nadir Hb, mean g/dL ±SD 14.6 ±3.6 14.8 ±3.5 0.155  10.8 ±2.4 10.6 ±2.5 0.001 
Last Hb, mean g/dL ±SD 15.3 ±3.2 15.4 ±3.2 0.374  11.5 ±2.0 11.3 ±2.0 <0.001 
n of patients transfused, 
n(%) 
223 (13.8) 219 (13.1) 0.485  726 (13.3) 661 (12.5) 0.211 
n of transfusions per patient, 
n(%) 
       
  0 1,389 
(86.2) 
1,465 (87.0)   4,747 
(86.7) 
4,645 (87.5)  
  1 76 (4.7) 81 (4.8)   278 (5.1) 275 (5.2)  
  2 42 (2.6) 40 (2.4)   207 (3.8) 171 (3.2)  
  3 21 (1.3) 21 (1.3)   81 (1.5) 68 (1.3)  
  4 21 (1.3) 16 (1.0)   58 (1.1) 58 (1.1)  
  5-9 33 (2.1) 43 (2.6)   82 (1.5) 68 (1.3)  
  ≥10 30 (1.9) 18 (1.1) 0.058  20 (0.4) 21 (0.4) 0.798 
n of transfusions to patients 
transfused ≥10 times, n(%) 
509 (49.9) 306 (35.3) <0.001  272 (13.8) 322 (18.0) 0.001 
Length of stay, median 
[IQR] 
3 [2-9] 4 [2-9] 0.413  3 [2-6] 3 [2-6] 0.378 





The incidence of transfusions in surgical patients (n=2,220) was 0.107 before the intervention 
and 0.103 after (IRR 0.960, p=0.424). Mean nadir hemoglobin was no different before and after 
the intervention (10.5±2.2 vs. 10.4±2.2, p=0.245), but the mean last hemoglobin was slightly 
lower in the time period after the intervention (11.2±1.9 vs. 11.0±1.9, p=0.014). The number of 
patients transfused (23.9% vs. 22.0%, p=0.288) and LOS (4 days [2-7] vs. 4 days [2-7], p=0.602) 
were not different. (Table 3.4) 
 
Table 3.4 Secondary Outcomes by Age Group & CDS intervention for Surgical Patients. 
 < 3 months   3 months to 18 years  
 Pre-CDS  
n=184 
Post-CDS  





Nadir Hb, mean g/dL 
±SD 
11.5  ±2.9 11.5 ±3.0 0.986  10.5 ±2.2 10.4 ±2.2 0.245 
Last Hb, mean g/dL ±SD 13.0 ±2.7 12.8 ±2.9 0.653  11.2 ±1.9 11.0 ±1.9 0.014 
n of patients transfused, 
n(%) 
83 (45.1) 74 (41.3) 0.469  275 (23.9) 236 (22.0) 0.288 
n of transfusions per 
patient, n(%) 
       
0 101 (54.9) 105 (58.7)   874 (76.1) 835 (78.0)  
1 23 (12.5) 25 (14.0)   89 (7.8) 77 (7.2)  
2 16 (8.7) 16 (8.9)   71 (6.2) 56 (5.2)  
3 11 (6.0) 10 (5.6)   41 (3.6) 30 (2.8)  
4 10 (5.4) 6 (3.4)   29 (2.5) 25 (2.3)  
5-9 15 (8.2) 14 (7.8)   38 (3.3) 40 (3.7)  
≥10 8 (4.4) 3 (1.7) 0.751  7 (0.6) 8 (0.8) 0.820 
Length of stay, median 
[IQR] 
15 [5-38] 14 [5-27] 0.548  4 [2-7] 4 [2-7] 0.602 
CDS, clinical decision support; Hb, hemoglobin. 
 
 
When excluding the frequently transfused patients, the difference in transfusion incidence before 
and after the intervention persisted. The incidence of transfusions per patient-day was 0.059 
37 
 
before the intervention and 0.052 after (IRR 0.876, p<0.001). The differences in secondary 
outcomes also remained: the mean nadir hemoglobin was 10.8±2.4 vs. 10.7±2.4 (p=0.001) and 
last hemoglobin was 11.5±2.0 vs. 11.3±2.0 (p<0.001). (Table 3.5) 
 
When combining both age groups, the incidence of transfusions per patient-day was 0.065 before 
the intervention and 0.058 after (a decrease of 10%). This reduction can be extrapolated to a 
decrease of 297 transfusions/year associated with the intervention in this size study population. 
 
Table 3.5 Outcomes by Age Group & CDS intervention excluding patients transfused ≥10 times 









Nadir Hb, mean g/dL 
±SD 
14.7 ±3.5 14.9 ±3.5 0.268  10.8 ±2.4 10.7 ±2.4 0.001 
Last Hb, mean g/dL 
±SD 
15.4 ±3.2 15.4 ±3.2 0.529  11.5 ±2.0 11.3 ±2.0 <0.001 
n of patients 
transfused, n(%) 
193 (12.2) 201 (12.1) 0.906  706 (13.0) 640 (12.1) 0.190 
Length of stay, 
median [IQR] 
3 [2-8] 4 [2-9] 0.259  3 [2-6] 3 [2-6] 0.407 





In addition to the crude IRR, four regression models were tested for each age group: a univariate 
NB model, a multivariate NB model, a univariate ZINB, and a multivariate ZINB . (Table 
3.6)The test for alpha on all the NB models was statistically significant, confirming that the data 
is better fit by the NB distribution compared to the Poisson. In addition, the AIC was better for 
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the ZI models, suggesting an improved predictability when weighting the highly frequent zero 
counts.  For patients <3 months of age, the IRR shifted towards the null as the regression model 
performed better (reduced AIC), with the best performing option being the ZINB model. The 
IRR for the multivariate ZINB model in the <3 month group was 0.972 (95%CI 0.821-1.150), 
negating the difference seen in the crude IRR within this age category. The models for the cohort 
of patients >3 months had the opposite effect, with the IRR shifting away from the null as the 
model performed better. The IRR for the multivariate ZINB model was 0.818 (95%CI 0.732-
0.914), confirming the significant decrease in the incidence of transfusion after the intervention 
within the > 3 months of age group of children. 
 
Table 3.6. IRR for the CDS prompt in different regression models     
 IRR 95%CI p SE z AIC 
< 3 months       
crude IRR 0.883 0.806-0.968 0.007    
univariate NB * 0.914 0.767-1.088 0.312 0.081 -1.01 3615 
multivariate NB ** 0.964 0.803-1.156 0.692 0.090 -0.40 3368 
univariate zero-inflated NB *** 0.980 0.832-1.153 0.805 0.082 -0.25 2756 
multivariate zero-inflated NB 0.972 0.821-1.150 0.739 0.838 -0.33 2653 
3 months to 18 years       
crude IRR 0.906 0.850-0.966 0.003    
univariate NB* 0.824 0.728-0.934 0.002 0.053 -3.03 12100 
multivariate NB** 0.833 0.734-0.946 0.005 0.054 -2.83 11609 
univariate zero-inflated NB*** 0.809 0.722-0.906 <0.001 0.047 -3.69 9934 
multivariate zero-inflated NB 0.818 0.732-0.914 <0.001 0.046 -3.55 9542 
IRR, incidence rate ratio; CDS, clinical decision support; SE, standard error; AIC, Akaike information 
criterion; NB, negative binomial. 
 
* negative binomial models using length of stay as exposure. 
** multivariate models adjusted for sex, age (in years), surgical patient and case-mix index 








This study evaluated the implementation of an evidence-based CDS tool within a large children’s 
hospital CPOE system as an intervention to reduce transfusions during neonatal and pediatric 
hospitalizations. After introducing the CDS tool, a significant decrease in the incidence of 
transfusion was noted amongst children >3 months of age. Specifically, when compared to the 
time period before the intervention, the incidence of transfusion in children >3 months of age 
decreased by 18% (IRR 0.818, p<0.001). Interestingly, however, the incidence of transfusion did 
not significantly change for children <3 months of age (IRR 0.972, p=0.739).  
 
The use of CDS in blood utilization has been reported previously within the pediatric population. 
Out of the four published pediatric studies, one specifically examined platelet and plasma 
transfusion,33 and another was focused on exchange transfusions in patients with sickle cell 
disease.34 Of the two studies that examined RBC transfusions, one was NICU specific while the 
other excluded NICU patients. Baer and colleagues introduced their institutional guidelines into 
a CDS algorithm for NICU patients. Their intervention was associated with a decrease in 
transfused patients from 19 to 13 percent (p<0.05).30 In 2011, Adams et.al. showed a significant 
decrease in the rate of transfusion with a prompt that reminded clinicians of the evidence that a 
hemoglobin threshold of 7g/dL is safe.29 In this study, patients in the NICU as well as those on 
cardiac and hematology/oncology wards were excluded.  The study showed a decrease in 
transfusions per patient day from 0.076 to 0.050 (p<0.03). We modeled our intervention in a 
similar way to this study but included a separate algorithm for patients in the NICU. In addition, 
due to the fact that our cardiac and hematology/oncology patients are not completely 
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geographically separate from the rest of the pediatric intensive care unit and general ward we 
chose to include them in our analysis. We did, however, exclude transplant patients and those on 




Fig 3.3 Monthly rates of transfusions per patient/day for patients >3 months of age. Solid red line 
is the incidence rate for the 12-month period. Dashed red line is the time of the clinical decision 
support intervention launch. The crude incidence rate ratio (IRR) was 0.906 (p=0.003). The IRR 
on the multivariate zero-inflated negative binomial regression model was 0.818 (p<0.001). 
 
 
A systematic review by Hibbs et.al. examining the use of CDS tools with regard to transfusion 
practices found only modest success. The study, which also included adult patients, found that of 
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the 13 studies included only 7 showed a statistically significant reduction in transfusions, of 
which two studies were mentioned previously above.37 Outcomes such as LOS and mortality 
were unchanged in most studies. The economic argument is a compelling one when analyzing 
the benefit of a health intervention and all of the studies in the systematic review by Hibbs et.al. 
were associated with a decrease in costs.37 The data behind monetary costs of a pediatric 
transfusion are limited. Since the actual financial burden of a blood transfusion is dependent on 
many factors such as volume, location of patient, characteristics of the RBC (e.g. leukoreduced, 
same donor, etc) we cannot safely extrapolate costs reported in publications of transfusions in 
adults to transfusions in children therefore cannot calculate an accurate amount on the economic 
effects of our intervention.38 
 
To investigate the effect of CDS tools on transfusions practices, multiple potential outcomes 
could be studied. The most commonly used metrics are monthly or aggregate rates of 
transfusion, mean pretransfusion hemoglobin, adherence to specific transfusion guidelines, 
number of transfusions per patient, and proportion of patients transfused. The mean 
pretransfusion hemoglobin offers an easy to compare continuous and likely normally distributed 
variable that can also report adherence to guidelines, but it is also resource intensive to collect. 
We used IMPACT Online as our primary data source, which automatically calculates counts of 
blood transfusions as well as first, nadir, and last hemoglobin. We chose to use transfusion rate 
as our outcome instead of pretransfusion hemoglobin due to the ease with which tranfusion rate 
can be ascertained and immediately translated to resource utilization. One of the limitations of 
the retrospective review of rates that we and other authors have encountered is that it can be 
greatly dependent on small changes in population characteristics and severity of disease within 
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the cohorts. We attempted to account for this limitation by creating regression models that adjust 
for age, sex, and severity of disease. 
 
One of the challenges that comes with analyzing counts in transfusion data is that most 
hospitalized patients do not require a transfusion. The excessive amount of zeros can 
compromise the interpretation of the comparison by ignoring the effect of not transfusing an 
anemic patient. By introducing a ZI model, a different approach is applied to a patient that was 
not transfused but had a low nadir hemoglobin compared to one that was never anemic and 
therefore had a negligible risk of getting transfused. ZI models include a binary (logit or probit) 
model with a count model (Poisson or NB) and have the same ability to introduce covariates as 
most regression models.39 While most studies of CDS effectiveness have used crude incidence 
rates, we believe that a ZI count model such as ZINB, hurdle, or Poisson (if the assumptions of 
its distribution hold) are more appropriate.40,41 In addition, we have shown that use of a ZI model 
may significantly alter inferences—in this study no difference in transfusion rates was found in 
infants <3 months when appropriately analyzed with a ZI model despite the crude IRR initially 
suggesting a difference. 
 
Randomized trial data supports the use of conservative hemoglobin thresholds for transfusion in 
pediatric patients, but the validation and widespread acceptance of the data has been slower in 
the neonatal population. Kirpalani et.al. conducted a randomized trial in extremely low birth 
weights comparing low and high hemoglobin triggers for transfusion.11 The study demonstrated 
no differences in complications between the two groups. However, there has been continued 
hesitancy to use restrictive hemoglobin thresholds in neonates, primarily due to the concern for 
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effects of anemia on the developing brain.42 Three years after the Kirpalani et.al. trial, a follow 
up study of the same patients showed a trend towards higher cognitive delay (24.4% in the low 
threshold group vs. 17.6% in the high, p=0.06) in the restrictive threshold group.22 This likely led 
to significant caution amongst neonatologists with regard to the their approach to anemia. Indeed 
an international survey showed widely varying approaches to hemoglobin thresholds among 
neonatologist, with a range of discrepancy around 2g/dL for most physicians.43 We suspect this 
concern for cognitive development and variability in beliefs about transfusion thresholds in the 
neonatal population amongst is why the CPS tool in this study failed to show a difference in 
transfusion rates in the <3 month age group. 
 
The data to support restrictive thresholds in older children is more widely accepted compared to 
neonates. The main trial supporting a hemoglobin of 7g/dL as a transfusion threshold was 
published in 2007 by Lacroix et.al. and showed no difference in morbidity when comparing it to 
a liberal threshold of 9.5g/dL.12 They excluded patients that were hemodynamically unstable or 
had acute blood loss, hemolytic anemia, or cardiovascular problems. Post-hoc subgroup analyses 
were done in septic, cardiac, and general surgical patients with concordant results showing no 
increase in adverse effects with restrictive thresholds.13,44,45 These and other studies were 
consolidated in 2018 into a group of recommendations from the Pediatric Critical Care 
Transfusion and Anemia Expertise Initiative that states “In critically ill children or those at risk 
for critical illness, who are hemodynamically stable and who have an hemoglobin concentration 
greater than or equal to 7g/dL, we recommend not administering a RBC transfusion.”.46 Despite 
this, the mean nadir hemoglobin of the patients >3 months of age in our cohorts was 10.6 g/dL to 
10.8 g/dL, questioning whether we had a significant volume of patients that fell out of the 
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generalizable population for the recommendations (e.g. unstable, cardiovascular problems) or 
whether institutional adherence to guidelines was simply that low. The institutional adherence to 
guidelines was examined in a Chapter 4. 
 
It is important to recognize the details of our inclusion and exclusion criteria and how that 
applies to a generalization of our findings. A significant proportion of blood products utilized in 
a hospital goes to a small number of patients. Most patients at high risk of frequent transfusions 
are trauma patients, critically ill patients on extracorporeal life support, critically ill premature 
infants, patients with hemorrhagic shock, bone marrow suppression, or an inherited blood 
disorder, or patients undergoing surgeries that are associated with high blood loss (e.g. cardiac 
surgery, spinal surgery).47 The CPOE intervention in this study was applied to every transfusion 
order that occurred in the wards (intensive care unit and general floor) but excluded transfusions 
in the operating room, in outpatient areas, and those associated with massive transfusion 
protocols. Patients that were transplanted (solid organ or bone marrow), had a trauma with a 
LOS ≤1 day, or who had been on extracorporeal life support or had a cardiovascular assist device 
placed were excluded. The rationale for this exclusion was the lack of evidence to support 
hemoglobin threshold in these particular populations and because trauma patients with a short 
LOS were either minimally injured and therefore discharged and not at risk of transfusion or so 
severely injured that they died, frequently from hemorrhagic shock and therefore making their 
blood requirements likely the result of activating a massive transfusion protocol. In addition, 
admissions that never had a hemoglobin checked were excluded, leading to an inflation of our 
transfusion per patient-day rate. These exclusions make comparison of transfusion rates between 
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hospitals unreliable but if maintained constant with a given institution may still allow for 
longitudinal analyses within that hospital.   
 
Several limitations of this study should be noted. From the methodological perspective, historical 
controls were used for comparison, and these data were obtained retrospectively, adding risk for 
potential bias. The data was analyzed with the assumption that the control and intervention 
cohorts were similar and had the same risk of receiving blood. Even though the regression 
models were adjusted for age, gender, and CMI, there is still potential for residual confounding. 
In addition, the exclusion criteria applied to the cohorts removed patients that potentially had 
high transfusion rates, which could skew the IRR significantly. Finally, this study focused on the 
impact of a CDS tool on transfusion rates, but the power of the intervention is certainly affected 
by the perceived strength of the data on which the CDS prompt is based. Clinicians consider 
many data points when making a decision to transfuse, and an improved intervention with 
physiologic parameters (e.g. blood pressure, heart rate, oxygen requirements, and measures of 




CDS is a useful tool to disseminate institutional guidelines and evidence-based practices. CDS 
providing guidance on hemoglobin thresholds for transfusion and embedded within a CPOE 
system decreased transfusion rates in pediatric patients but not amongst the youngest neonates, a 
population in whom the evidence for transfusion thresholds is less robust. Comparisons of 
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transfusion practices over time should utilize a statistical model that appropriately accounts for 




























In this chapter, we report our adherence to the guidelines described in chapter 3 as well as the 
indications that patients have when receiving transfusions outside of recommended thresholds. 
Transfusions from August 28, 2013 to October 31, 2014 at the JHBCC were analyzed. The 
primary outcome was the proportion of transfusions compliant with hemoglobin-level based 
recommendations. This was studied for both age groups and for each hospital location (NICU, 
PICU and regular inpatient floor). Our final cohort consisted of 1,955 pediatric transfusions of 
which 1,104 occurred in patients <3 months of age or in the NICU and 851 in patients >3 months 
of age. The proportion of compliant transfusion orders in patients <3 months of age varied by 
hospital location with 386 (42.6%) compliant transfusions in the NICU, 116 (63.4%) in the PICU 
and 13 (92.9%) in the floor ward (p<0.001). The same variation occurred in children >3 months, 
with 158 (27.8%) compliant transfusions in the PICU and 141 (50.0%) in the acute care floor 
(p<0.001). The most common indications stated by providers were active cardiac disease, active 
bleeding and symptomatic anemia. As hospitals implement guidelines for transfusion practices it 
is relevant to constantly evaluate institutional adherence and identify populations where 









There are multiple variables that are considered when deciding to give a blood transfusion. It is 
relevant to recognize the child’s physiology, age, oxygen delivery, bone marrow activity, acute 
blood loss, surgical plan, among other factors. One of the most universal markers that clinicians 
take into account is the hemoglobin (Hb) level. Even though Hb is a single variable in the 
equation, it offers an easy to measure, trackable and dynamic variable that can indicate the need 
of a blood transfusion. The most relevant studies in anemia tolerance of hospitalized patients 
have used Hb level as the trigger to transfuse 
 
Randomized trials to study restrictive hemoglobin thresholds have been done in pediatrics for 
more than a decade. Bell et.al. first published a study 2005 in 100 preterm infants with weight of 
500 to 1300g. Their restrictive threshold was defined depending on the patients respiratory level 
of support, ranging from a hematocrit from 22 to 34 (Hb approximately 7.3 to 11.3 g/dL) and the 
liberal from 30 to 46 (Hb approximately 10 to 15.3 g/dL). As expected, the infants in the 
restrictive threshold received less transfusions but also had an increase in grade 4 intraventricular 
hemorrhage (0% vs. 8 %, p=0.012) and apneic episodes per day requiring stimulation (0.23 vs. 
0.42, p=0.002).48 Their study was followed by the PINT study, an RCT by Kirpalani et. al. 
published in 2006. They focused on ELBW (<1000 grams at birth) infants and enrolled 451 
subjects. Their restrictive threshold for capillary Hb ranged from 7.5 to 11.5 g/dL and the liberal 
was 8.5 to 13.5 g/dL. The short-term results of this larger trial did not show outcome differences 
between threshold approaches, suggesting that neonates could tolerate anemia better than what 
we were allowing.11 But in 2009 the same group of authors published a follow up on the same 
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cohort that raised concerns for increased occurrences of neurosensory impairment (29% vs. 22%, 
p=0.07) and cognitive delay (24% vs. 18%, p=0.06) in the restrictive threshold patients.22 These 
trials were instrumental in establishing our institutional recommendations, where we used the 
thresholds established in the liberal strategy from the PINT study.  
 
The other landmark trial for the use of hemoglobin thresholds in RBC transfusions was the 
TRIPICU study. This was published by Lacroix and colleagues in 2007 and included 637 
critically ill children from multiple institutions around the world. They enrolled subjects from 3 
days of age to 14 years but their average patient age was 3 years old and they only studied 19 
patients that were 28 days. This questions the generalizability of the findings to neonates. They 
excluded patients that were bleeding, hemodynamically unstable, had cardiovascular problems or 
hemolysis among other criteria. Their restrictive threshold was 7 g/dL and the liberal was 9.5 
g/dL.12 There were no differences in any of the outcomes studied and their non-inferiority was 
re-established in multiple subset analysis in septic, cardiac surgery and general surgical 
patients.13,44,45  
 
Using the evidence reported in these trials, we created institutional recommendations for the use 
RBCs based on hemoglobin thresholds. These guidelines were crafted by a working group of 
pediatric, anesthesia and surgical providers. We then introduced a clinician decision support 
(CDS) logic into our computerized provider order entry (CPOE) system to collect information 
about transfusions that were ordered outside of the recommended thresholds. (Chapter 3) In this 
analysis, we sought to evaluate our adherence to these recommendations as well as the 
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indications that patients have when receiving transfusions when the hemoglobin level is higher 




In the same way as the study reported in Chapter 3, patients were stratified in two groups as the 
recommendations and CDS prompt varied depending on their age and location.(Table 3.1) Group 
1 were those from 0 to 3 months (≤90days) of age or located in the NICU and Group 2 included 
patients > 3months (>90 days) to 18 years. This “soft” stop only appeared when the 
pretransfusion hemoglobin was ≥7g/dL on patients > 3 months of age and ≥8.5g/dL in patients 0 
to 3 months of age or located in the NICU. Although institutional recommendations included 
higher hemoglobin levels for neonates with respiratory support, a single trigger of ≥8.5g/dL was 
used for patients 0 to 3 months of age and “transfusion is compliant with guidelines” was 
included as one of the choices to transfuse outside of the pre-established institutional 
recommendations. The pre and post analyses of this CDS addition is reported in Chapter 3. This 
analysis includes a detailed description of the transfusions occurring in the 14 months after the 




Transfusions from August 28, 2013 to October 31, 2014 at the JHBCC were analyzed. We 
included allogeneic packed red blood cell transfusions in patients that were 0 to 18 years of age 
at the time of transfusion. Data were obtained in daily reports of transfusions ordered within the 
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time of evaluation and pre and post-transfusion hemoglobin was extracted from the patient’s 
chart. Other data included in the daily reports were location, ordering provider and service. The 
indication to transfuse was also reported in patients that were transfused outside of the 
hemoglobin thresholds included in institutional recommendations.  
 
We excluded intraoperative transfusions as these were ordered through a different CPOE system 
and recommendations for blood use in these patients respond to different circumstances than the 
ones outside of the operating room. Patients that were transfused under massive transfusion 
protocols, on ECMO or had a transplant (solid or bone marrow) were also excluded.  
Demographic variables and specific characteristics associated with the transfusion order were 
analyzed including age, sex, volume transfused (ml/kg or units), role of ordering provider (e.g. 
resident, fellow, nurse practitioner, etc) and location of the patient. 
 
Subset analyses were performed to assess the adherence to transfusion recommendations in 
cardiac surgery patients (defined as having an ICD9 procedure code between 35.00 and 39.99 as 




The primary outcome was the proportion of transfusions compliant with hemoglobin-level based 
recommendations. This was studied for both age groups and for each hospital location (NICU, 
PICU and regular inpatient floor). Compliant was defined as a transfusion that occurred when the 
hemoglobin was under the thresholds stated by the recommendations. These are 13.5g/dL in 
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patients 1 to 7 days old, 12 g/dL in patients 8 to 14 days and 10 g/dL in patients 15 days. The 
recommendations specify lower Hb thresholds for neonates without respiratory support, but we 
only used the higher thresholds to define compliance. For children >3 months a transfusion was 
declared compliant if the Hb was <7 g/dL.  
 
Secondary outcomes included the mean pretransfusion and post-transfusion hemoglobin. The 
mean change in the hemoglobin level resulted from each transfusion was also investigated and 
analyzed by high or low volume transfusions. Low volume was defined as those orders for ≤10 
ml/kg and high was >10 ml/kg. For patients that were transfused in units of PRBCs, the volume 
was calculated by multiplying the number of units by 350 and dividing the volume by their 
weight. The mean volume transfused was compared by ordering hospital unit. 
 
In addition to investigating transfusions individually, we analyzed outcomes by patient. We 
studied the number of patients with all transfusions compliant, number of transfusions per patient 
and the number of different indications for repeated non-compliant transfusions. 
 
Statistical comparison of normally distributed variables was conducted with t test or ANOVA 
and chi-square for categorical variables. Statistical analysis was conducted with STATA/MP 






A total of 2,928 transfusions were screened for our analysis. We excluded transfusions in adults 
(n=153), transfusions in patients on ECMO or VAD (n=597), heart transplant (n=131), liver 
transplant (n=19), kidney transplant (n=6), bone marrow transplant (n=65) and from an unknown 
location (n=2). Our final cohort consisted of 1,955 pediatric transfusions of which 1,104 
occurred in patients <3 months of age or in the NICU and 851 in patients >3 months of age. (Fig 
4.1) 
 
Group 1- Transfusions in patients <3 months of age or in the NICU 
 
The median age at transfusion was 22 days [8-48]. A total of 243 (22.0%) transfusions occurred 
in patients 0 to 7 days, 181 (16.4%) in neonates 8 to 14 days, 601 (54.4%) in patients 15 to 90 
days and 79 (7.2%) in infants >3 months of age that were still in the NICU. More than half of the 
transfusions were in male babies (594, 53.8%). A significant amount of transfusions were 
allocated to patients transfused >10 times (n=359, 32.5%). Most transfusions were ordered as 15 
ml/kg (n=753, 68.2%) with 10 ml/kg (n=300, 27.2%) as the second most frequent order. There 
were four transfusions that were ordered as one or two units which may have occurred as an 
ordering error. The most frequent ordering providers were residents (n=505, 45.7%) and nurse 
practitioners (n=452, 40.9%). It is important to recognize that the decision to transfuse is not 
necessarily made by the ordering provider as there were nine transfusions (0.8%) ordered by a 
medical student. As expected, the majority of transfusions within this age group occurred in the 
NICU (n=907, 82.2%) with PICU following (n=183, 16.6%) and the occasional transfusions 





Fig 4.1 Transfusion flow chart and exclusion criteria.  
ECMO, extracorporeal membrane oxygenation; VAD, ventricular assist device. 
 
 
The proportion of compliant transfusion orders varied by hospital location with 386 (42.6%) 
compliant transfusions in the NICU, 116 (63.4%) in the PICU and 13 (92.9%) in the floor ward 
(p<0.001). (Table 4.2) The hemoglobin thresholds decrease as patients get older and so does the 
institutional adherence to recommendations. For patients <8 days, 206 transfusions (84.8%) were 
compliant and this decreased to the point that only 2 (2.5%) transfusions were under 
recommended thresholds in patients >3 months in the NICU. (Figure 4.2) 
 
A histogram of the pretransfusion Hb was graphed to evaluate for distribution and outliers. The 
data appeared to be normally distributed without excessive kurtosis. (Figure 4.3) The 
pretransfusion Hb was significantly different by location. For transfusions in patients 0 to 7 days  
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Table 4.1. Characteristics of Transfusions and Patients. 
 Group 1                                        
<3 months or NICU           
(n=1,104) 
Group 2                                     
3 months to 18 years          
(n=851) 
Age, median [IQR] 22 days [8-48] 4 years [1-13] 
Age category, n (%)   
   0 to 7 days 243 (22.0)  
   8 to 14 days 181 (16.4)  
   15 to 90 days 601 (54.4)  
   3 months to 1 year 79 (7.2) 197 (23.2) 
   1 to 10 years  367 (43.1) 
   11 to 18 years  287 (33.7) 
Sex, female n(%) 510 (46.2) 398 (46.9) 
Transfusions to patients 
transfused >10 times 
359 (32.5) 117 (13.8) 
Volume transfused   
    <10 ml/kg 35 (3.2) 88 (10.3) 
    10 ml/kg 300 (27.2) 293 (34.4) 
    15 ml/kg 753 (68.2) 153 (18.0) 
    20 ml/kg 12 (1.1) 32 (3.8) 
    1 unit 2 (0.2) 175 (20.6) 
    2 units 2 (0.2) 102 (12.0) 
    Other 0 8 (0.9) 
Ordering provider   
    Medical Student 9 (0.8)  
    Resident 505 (45.7) 462 (54.3) 
    Fellow 115 (10.4) 256 (30.1) 
    Attending 12 (1.1) 34 (4.0) 
    Nurse Practitioner 452 (40.9) 94 (11.1) 
    Physician Assistant 1 (0.1) 5 (0.6) 
    Other   
Location   
    NICU 907 (82.2)  
    PICU 183 (16.6) 569 (66.9) 
    Acute care ward 14 (1.3) 282 (33.1) 
NICU, neonatal intensive care unit; PICU, pediatric intensive care unit 
 
the mean pretransfusion Hb in the NICU was 11.9 1.3 g/dL and 12.5 2.0 g/dL in the PICU 
(p=0.026). There were no transfusion orders for patients <15 days old on the floor ward. For 
neonates 8 to 14 days of age, the mean pretransfusion Hb in the NICU was 11.7 1.2 g/dL vs. 
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11.1 2.1 g/dL in the PICU (p=0.041). For patients 15 to 90 days old, the mean pretransfusion 
Hb in the NICU was 11.0 1.4 g/dL, 9.3 2.3 in the PICU and 7.2 1.2 in the regular floor ward 
(p<0.001). (Table 4.2) 
 
Table 4.2 Adherence to Guidelines and Hb Levels for Transfusions 
 Group 1                                                                           
< 3 months or older in NICU 
Group 2                              
3 months to 18 years 
 NICU          
n=907 
PICU      
n=183 
Floor                   
n=14 p  
PICU       
n=569 
Floor      
n=282 p 
Adherent to 
guidelines, n(%) 386 (42.6) 
116 
(63.4) 13 (92.9) <0.001  158 (27.8) 141 (50.0) <0.001 
Pretransfusion Hb, 
mean g/dL ±SD 
        
   0 to 7 days 11.9 ±1.3 12.5 ±2.0 n/a 0.026     
   8 to 14 days 11.7 ±1.2 11.1 ±2.1 n/a 0.041     
   15 to 90 days  11.0 ±1.4 9.3 ±2.3 7.2 ±1.2 <0.001     
   3 months to 1y*      10.5 ±1.9 7.0 ±1.6 <0.001 
   1 to 10 years      8.7 ±3.2 6.8 ±1.3 <0.001 
   11 to 18 years      7.5 ±1.5 7.4 ±1.3 0.353 
Post-transfusion 
Hb, mean g/dL ±SD 
        
   0 to 7 days 14.3 ±1.8 14.0 ±1.8 n/a 0.3255     
   8 to 14 days 14.1 ±1.5 12.9 ±2.4 n/a <0.001     
   15 to 90 days  13.7 ±1.6 11.7 ±2.4 11.8 ±2.7 <0.001     
   3 months to 1y*      12.4 ±1.8 10.0 ±2.3 <0.001 
   1 to 10 years      10.9 ±2.6 9.4 ±1.9 <0.001 
   11 to 18 years      9.5 ±1.8 9.3 ±1.5 0.331 
Change in Hb, mean 
g/dL ±SD 
        
   0 to 7 days 2.4 ±1.8 1.5 ±1.4 n/a 0.003     
   8 to 14 days 2.5 ±1.5 1.8 ±1.4 n/a 0.018     
   15 to 90 days  2.8 ±1.6 2.4 ±1.3 4.4 ±2.6 <0.001     
   3 months to 1y*      1.9 ±1.7 3.0 ±1.9 0.007 
   1 to 10 years      2.2 ±1.6 2.6 ±1.5 0.014 
   11 to 18 years      1.9 ±1.5 1.9 ±1.4 0.816 
* the 79 tranfusions that were >3mo and in the NICU were excluded for mean hgb comparisons 




The post-transfusion or goal Hb for neonates in the first week of life did not differ by unit. The 
mean post-transfusion Hb in the NICU was 14.3 1.8 g/dL and 14.0 1.8 g/dL in the PICU 
(p=0.3255). For neonates 8 to 14 days of age, the mean post-transfusion Hb in the NICU was 
14.1 1.5 g/dL vs. 12.9 2.4 g/dL in the PICU (p<0.001). For patients 15 to 90 days old, the 
mean post-transfusion Hb in the NICU was 13.7 1.6 g/dL, 11.7 2.4 in the PICU and 11.8 2.7 
in the regular floor ward (p<0.001). (Table 4.2) 
 
 
Figure 4.2 Percent adherence to guidelines in patients <3 months of age or in the neonatal intensive care unit by age 
group.  




The change in Hb for patients across almost all age groups was markedly different depending on 
the ordering unit. The mean change in Hb in the NICU was 2.4 1.8 g/dL and 1.5 1.4 g/dL in 
the PICU (p=0.003). For neonates 8 to 14 days of age, the mean change in Hb in the NICU was 
2.5 1.5 g/dL vs. 1.8 1.4 g/dL in the PICU (p=0.018). For patients 15 to 90 days old, the mean 
change in Hb in the NICU was 2.8 1.6 g/dL, 2.4 1.3 g/dL  in the PICU and 4.4 2.6 g/dL  in 
the regular floor ward (p<0.001). (Table 4.2) 
 
 
Figure 4.3 Histogram of pretransfusion Hb by age groups. For patients <3 months of age or in the neonatal intensive 
care unit (blue) there seems to be a normal distribution. For transfusions in patients >3 months (red), there is a 
bimodal-like distribution with a peak at 7 g/dL and a second peak at 11 g/dL.  
 
 
The magnitude of the difference in mean change in Hb is concordant with the differences seen in 
volume ordered by each unit. Patients 0 to 7 days old were transfused 13.8 ±2.4 ml/kg in the 
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NICU and 9.8 ±3.3 ml/kg in the PICU (p<0.001). Neonates 8 to 14 days old received 13.8 ±2.3 
cc/kg in the NICU and 10.0 ±3.7 in the PICU (p<0.001). Infants 15 to 90 days were ordered 14.0 
±2.2 ml/kg in the NICU, 11.0 ±3.2 ml/kg in the PICU and 13.1 ±3.8 in the regular floor ward 
(p<0.001). (Table 4.3) It is important to note that five transfusions had a significantly high outlier 
volume due to the fact that they were ordered as full units in small patients. These entries may 
represent an error in the way the RBCs were ordered therefore we excluded them to allow for 
improved comparison of mean values. The increase in Hb associated with a low volume 
transfusion was 2.0 g/dL vs. 3.0 in high volume transfusions (p<0.001) (Figure 4.4.A) 
 
Table 4.3 Volume Characteristics of Transfusions by Age Group and Hospital Location 
 Group 1                                                
< 3 months or older in NICU 
Group 2                                 
3 months to 18 years 
 NICU          
n=905 
PICU      
n=181 
Floor                   
n=14 p  
PICU       
n=568 
Floor      
n=282 p 
Transfusion volume 
(ml/kg), mean ±SD 
        
   0 to 7 days 13.8 ±2.4 9.8 ±3.3 n/a <0.001     
   8 to 14 days * 13.8 ±2.3 10.0 ±3.7 n/a <0.001     
   15 to 90 days * 14.0 ±2.2 11.0 ±3.2 13.1 ±3.8 <0.001     
   3 months to 1 y *      10.4 ±3.0 12.3 ±4.9 0.009 
   1 to 10 years      11.6 ±5.3 13.4 ±4.9 0.002 
   11 to 18 years      9.7 ±4.4 10.0 ±4.2 0.519 
*5 transfusions were excluded from group 1. These were >100cc/kg (full PRBC units ordered in 
infants) 
NICU, neonatal intensive care unit; PICU, pediatric intensive care unit 
 
 
Transfusions involving the same patients were also analyzed to report patient-specific outcomes. 
Since transfusions could occur at different locations throughout the hospital stay of the same 
patient, we did not report location comparisons. 121 patients (40.2%) in group 1 had all of their 
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transfusion orders within threshold recommendations. Most of the transfused patients received 
only one transfusion (n=128, 42.5%) but 27 patients (9.0%) received 10 transfusions. For the 
patients that received at least two transfusions outside of recommended thresholds, only 56 
(40.6%) had a consistent indication and 6 patients (4.4%) had more than five indications listed. 
(Table 4.4) 
 
The most frequent indications to transfuse outside of institutional recommendations were: active 
cardiac disease (n=58, 9.9%), symptoms attributed to anemia (n=256, 43.5%), transfusion is 
compliant (n=114, 19.4%), active bleeding (n=56, 9.5%) and “Other” (n=55, 9.3%). Even though 
the ordering provider used the “transfusion is compliant” option in 267 transfusions, these were 
not compliant in 114 occasions based on the pretransfusion threshold. (Figure 4.5) 
 
Group 2- Transfusions in patients >3 months of age 
 
The median age at transfusion was 4 years [1-13]. A total of 197 (23.2%) of transfusions 
occurred in patients 3 months to 1 year, 367 (43.1%) in children 1 to 10 years and 287 (33.7%) in 
patients 11 to 18 years. More than half of the transfusions were in male children (451, 53.1%). 
Compared to patients in group 1, a smaller number of transfusions were allocated to patients 
transfused >10 times (n=117, 13.8%). Different than group 1, transfusions were frequently 
ordered as 10 ml/kg (n=293, 34.4%) with 1 unit (n=175, 20.6%) as the second most frequent 
order. The most frequent ordering providers were residents (n=462, 54.3%) and fellows (n=256, 
30.1%). The majority of transfusions within this age group occurred in the PICU (n=569, 66.9%) 
with the rest in the floor ward (n=282, 33.1%). (Table 4.1) 
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Table 4.4 Transfusion Outcomes by Patient (n=733) 
 Group 1                                                                                   
< 3 months or older in NICU 
Group 2                                    
3 months to 18 years 
 n=301 n=432 
All transfusions 
compliant, n(%) 
121 (40.2) 151 (35.0) 
n of transfusions per patient   
   1 128 (42.5) 288 (66.7) 
   2 49 (16.3) 70 (16.2) 
   3 28 (9.3) 31 (7.2) 
   4 18 (6.0) 15 (3.5) 
   5 to 9 51 (16.9) 20 (4.6) 
   ≥10 27 (9.0) 8 (1.9) 
n of different indications for repeated 
 non-compliant transfusions 
 
   same indication 56 (40.6) 67 (57.8) 
   2 44 (31.9) 37 (31.9) 
   3 23 (16.7) 9 (7.8) 
   4 9 (6.5) 1 (0.9) 
   ≥5 6 (4.4) 1 (0.9) 
NICU, neonatal intensive care unit. 
 
 
The proportion of compliant transfusion orders varied by hospital location in this patient group 
too, with 158 (27.8%) compliant transfusions in the PICU and 141 (50.0%) in the acute care 
floor (p<0.001). (Table 4.2) When analyzed by more detailed age groups, infants 3 months to 1 
year had the lowest compliance (n=25, 12.7%) and patients 11 to 18 years the highest (n=122, 
42.5%). (Figure 4.6) 
 
A histogram of the pretransfusion Hb was graphed to evaluate for distribution and outliers. The 
data appeared to be bimodal with the main peak at a hemoglobin level of 7 g/dL and a second 
smaller peak around 11 g/dL. (Figure 4.3) The pretransfusion Hb was significantly different by 
location. For transfusions in patients 3 months to 1 year the mean pretransfusion Hb in the PICU 
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was 10.5 1.9 g/dL and 7.0 1.6 g/dL in the floor ward (p<0.001). For children 1 to 10 years of 
age, the mean pretransfusion Hb in the PICU was 8.7 3.2 g/dL vs. 6.8 1.3 g/dL in the acute 
care ward (p<0.001). For patients 11 to 18 years, the mean pretransfusion Hb in the PICU was 
7.5 1.5 g/dL and 7.4 1.3 in the regular floor ward (p<0.353). (Table 4.2) 
 
 
The post-transfusion or goal Hb also differed by unit. For infants 3 months to 1 year, the mean 
post-transfusion Hb in the PICU was 12.4 1.8 g/dL and 10.0 2.3 g/dL in the acute care ward 
(p<0.001). For children 1 to 10 years, the mean post-transfusion Hb in the PICU was 10.9 2.6 
g/dL vs. 9.4 1.9 g/dL in the acute care ward (p<0.001). For patients 11 to 18 years old, the 
mean post-transfusion Hb in the PICU was 9.51.8 g/dL and 9.3 1.5 in the regular floor ward 
(p=0.331). (Table 4.2) 
 
The change in Hb for patients by unit followed a similar pattern than the pre and post-transfusion 
Hb, it was different for the younger age groups but the same for patients 11 to 18 years of age. 
The mean change in Hb in the PICU was 1.9 1.7 g/dL and 3.0 1.9 g/dL in the acute care ward 
(p=0.007). For children 1 to 10 years of age, the mean change in Hb in the PICU was 2.2 1.6 
g/dL vs. 2.6 1.5 g/dL in the floor ward (p=0.014). For patients 11 to 18 years old, the mean 





As in the case of group 1, there were differences in the mean transfusion volume ordered by unit. 
For infants 3 months to 1 year in the PICU the mean volume transfused was 10.4 ±3.0 ml/kg and 
12.3 ±4.9 ml/kg in the acute care ward (p=0.009). Children 1 to 10 years received 11.6 ±5.3 
ml/kg in the PICU and 13.4 ±4.9 ml/kg in the regular floor ward (p=0.002). Patients 11 to 18 
years were ordered 9.7 ±4.4 ml/kg in the PICU and 10.0 ±4.2 ml/kg in the regular floor ward 
(p=0.519). (Table 4.3) The increase in Hb associated with a low volume transfusion was 2.0 g/dL 
vs. 2.7 in high volume transfusions (p<0.001) (Figure 4.4.B) 
 
 
Figure 4.4 Hemoglobin change by transfusion volume. High volume (blue) is >10 ml.kg and low volume (pink) is 
≤10 ml/kg. Each line is a transfusion and dotted thick lines are the mean for the volume group. (A) Transfusions in 
patients <3 months of age or in the neonatal intensive care unit. Mean hemoglobin change for low volume was 2.0 
g/dL and for high volume was 3.0 g/dL (p<0.001). (B) Transfusions in patients >3 months of age. Mean hemoglobin 





In group 2 (patients > 3months of age), 151 patients (35.0%) had all of their transfusion orders 
within threshold recommendations. The majority of transfused patients received only one 
transfusion (n=288, 66.7%) and 8 patients (1.9%) received 10 transfusions. For the patients that 
received at least two transfusions outside of recommended thresholds, only 67 (57.8%) had a 
consistent indication. (Table 4.4) 
 
 
Figure 4.5 Indications to transfuse outside of recommendations for patients <3 months of age or in the neonatal 
intensive care unit. The reason “Transfusion is Compliant” was checked by the provider but the pretransfusion 





The most frequent indications to transfuse outside of institutional recommendations were: active 
bleeding (n=156, 28.3%), active cardiac disease (n=150, 27.2%) and symptoms attributed to 
anemia (n=110, 19.9%). (Figure 4.7) When focusing on the transfusions that occurred with a 
pretransfusion Hb >10 g/dL, the majority of them were because of active cardiac disease (n=120, 
53.3%) 
 
Figure 4.6 Percent adherence to guidelines in patients >3 months of age. 
mos, months; y, year/s 
 
 




There were 415 transfusions in patients that underwent a cardiac surgery procedure during their 
hospital stay. The mean pretransfusion hemoglobin for transfusions in patients with cardiac 
disease was higher than the rest of the transfusions. For transfusions in infants <3 months of age 
(n=214) the pretransfusion Hb was 11.3 ±1.6 g/dL, for patients 3 months to 1 year (n=93) was 
10.6 ±1.8 g/dL, for children 1 to 10 years (n=74) the pretransfusion Hb was 11.2 ±3.3 g/dL and 
for the transfusions in patients 11 to 18 years (n=28) the Hb was 8.7 ±1.3 g/dL. The transfusions 
were compliant with recommendations in only 108 cases (26.0%). (Figure 4.8) The most 
common indications to transfuse in this population were active cardiac disease (n=110, 35.8%), 
active bleeding (n=78, 25.4%) and symptoms attributed to anemia (n=65, 21.2%) 
 
 






The present analysis shows an institutional report on adherence to hemoglobin-based 
recommendations for pediatric blood transfusions. For infants less than three months, 
institutional guidelines suggest a dynamic threshold for transfusion from 8.5 to 13.5 g/dL 
depending on age and respiratory support. For children > 3 months, our guideline defined a Hb 
of 7 g/dL to transfuse hemodynamically stable patients without compromise in oxygen delivery. 
We found that more than half of transfusions at our institution are given above the recommended 
thresholds and this varied by hospital unit. The most common indications stated by providers 
were active bleeding and active cardiac disease. In addition, we identified different practices in 
volume of transfusion depending on the hospital unit were the transfusion was ordered.  
 
Our adherence to guidelines was 46.7% when transfusing patients 0 to 3 months of age and 
35.1% in those given to children >3 months. We believe that there are several possible reasons 
why our adherence was low: (1) a significant amount of patients fell into an exception category 
within the guidelines (e.g. active bleeding, active cardiac disease); (2) practitioners were hesitant 
to adhere to guidelines for concerns in the quality of the data supporting them; (3) A Hb 
threshold of 7 g/dL is low for some congenital heart disease (CHD) patients and our analysis 
includes these population as there is not a separate cardiac unit at our hospital; (4) there was not 





Figure 4.8 Percent adherence to guidelines in cardiac surgery patients. 
mos, months; y, year/s 
 
 
In the case of patients <3 months of age, the low adherence is likely due to lack of strong 
evidence to support Hb thresholds for transfusion. The PINT study authors reported a trend 
towards an increased cognitive delay and neurosensory impairment in a follow up report on the 
patients that were randomized to restrictive Hb tresholds.22 For this reason, our guidelines for the 
youngest infants were based on the liberal thresholds of the PINT study. The most common 
indication to transfuse outside of recommended thresholds was symptomatic anemia (43%). 
There are two randomized trials currently registered that will offer additional high-quality 
evidence into the use of thresholds to transfuse premature infants. The Transfusion of Prematures 
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(TOP) trial has stopped recruiting and the Effects of Transfusion Thresholds on Neurocognitive 
Outcome of ELBW infants (ETTNO) has been completed but not published yet.49 
 
For patients outside of a NICU setting, the evidence behind restrictive Hb thresholds for 
transfusion is more robust but there are signs that this is still not universally accepted. An 
international survey of 97 pediatric intensivists by Du Pont-Thibodeau et/al. reported an increase 
from 1997 to 2010 in the number of physicians who use a threshold of 7 g/dL to consider 
transfusing a stable critically ill child. Nevertheless, only 8.3% of the respondents reported 7 
g/dL as a threshold for a scenario of a patient with septic shock and 16% in a scenario of repaired 
tetralogy of Fallot.50 Institutional reports of adherence to pediatric transfusion guidelines are 
scarce. To our knowledge the only recent study was published in 2019 by Badke et. al. They 
report that in a 40-bed PICU at a large Children’s Center, 53.3% of transfusions were given for a 
Hb ≤7 g/dL.51 This is higher than our institution possibly due to the fact that they did not include 
patients in the cardiac care unit and our PICU includes primary cardiac patients.  
 
In 2018, the Pediatric Critical Care Transfusion and anemia Expertise Initiative (TAXI) 
published a series of extensive recommendations for the use of blood products in pediatric 
patients.52,53 Transfusions over a Hb of 7g/dL should be considered for a few indications on 
hemodynamically stable children. In addition, for patients with cardiac disease, the TAXI group 
establishes weak recommendations to maintain a Hb between 7-9 g/dL in patients with 
uncorrected CHD and to avoid transfusion above 9 g/dL in single ventricle patients with 
adequate oxygenation (for their cardiac lesion) and normal end organ function. For patients with 
pulmonary hypertension or myocardial dysfunction, there was a consensus in the panel to state 
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that there is no evidence of a benefit in transfusing above 10 g/dL. In our study, there were 219 
transfusions given on patients >3 months when the pretransfusion Hb was >10 g/dL.54 The main 
indication for these transfusions was active cardiac disease in 120 occasions (54.8%) and active 
bleeding in 68 (28.8%). It is important to note that our analysis was performed with transfusions 
that occurred in 2013 and 2014 and as these data and recommendations become available the 
number of transfusions with Hb levels this high may be different. 
 
We noticed a significant variability in the ml/kg volume ordered by different units. In patients 
within the same age group, providers in the NICU, PICU and acute care ward ordered 
transfusions differently. As an example, in patients 15 to 90 days old, the mean transfusion 
volume in the NICU was 14.0 ml/kg, in the PICU 11.0 ml/kg and the acute care ward 13.1 ml/kg. 
While these discrepancies may be explained by variation in disease profiles, they are most likely 
related to unit-specific practices, where the NICU and floor most commonly order transfusions 
as 15ml/kg and the PICU does by 10ml/kg. A RCT published by Khodabux and colleagues 
showed that, while higher volume transfusions lead to less transfusion events in premature 
neonates, there is no difference in morbidity and long term neurodevelopmental outcomes when 
using 15cc/kg instead of 20cc/kg.55,56 An additional concern is that patients receiving >120ml/kg 
are at risk of developing iron overload and toxicity.57 One of the main motivations for higher 
volume transfusions is the potential reduction of donor exposure on premature neonates. This has 
been addressed at some institutions by establishing single-donor protocols but its implementation 
is controversial as it leads to the use of RBCs that have been stored for a longer time.58–60 We 
stratified transfusions by low (≤10 ml/kg) and high (>10ml/kg) volume and there was a 
difference in the change in Hb in both age categories (2.1 vs. 3.0 g/dL in infants <3 months and 
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2.0 vs 2.7 g/dL in children >3 months). Adult literature has supported lower volume transfusions 
and single-unit transfusion programs have led to more significant decreases in RBC utilization 
than using restrictive thresholds.61,62 While further data is needed in premature babies, we 
believe that adult data is translatable to older children and smaller volumes of transfusion should 
be preferred.63  
 
There are several limitations to our analysis. Our data source was directly extracted from our 
CPOE system and only transfusions that occurred in inpatient wards are included, therefore 
patients transfused in the operating room or as an outpatient are missed. In addition, we excluded 
transplant and extracorporeal life support patients which can account for a significant volume of 
RBC utilization. While the prescriber was required to select an indication to transfuse out of Hb 
recommendations, we did not audit their selection and there is a risk that fatigue associated to 
indication selection made the response inaccurate, a sign of this may be that only 40-60% had a 
consistent indication when given to the same patient. We did not investigate for physiologic and 
perfusion parameters around the time of transfusions, therefore we cannot conclude if the 
adherence rates reported were appropriately low.   
 
CONCLUSION 
Randomized trials have shown non-inferiority of restrictive Hb thresholds for RBC transfusions 
and this has guided the development of institution-specific recommendations as a measure to 
optimize blood utilization. While this is high-quality evidence, there is a significant number of 
patients where the results cannot be generalized. At our institution, close to half of the 
transfusions were given outside of recommended Hb thresholds. The most common indications 
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were cardiac disease, active bleeding and symptomatic anemia. As hospitals implement 
guidelines for transfusion practices it is relevant to constantly evaluate institutional adherence 
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